Guangzhou Ruixin Biotechnology

Guangzhou Ruixin Biotechnology is a clinical-stage biopharmaceutical company based in Guangzhou, China, focused on the discovery and development of innovative small molecule therapeutics for oncology. The company's lead candidate, RX-108, is a first-in-class Na+/K+-ATPase inhibitor currently being evaluated in Phase 2 clinical trials for various solid tumors, including glioma. Another key asset, RX-208, is a potent BRAF V600E inhibitor targeting melanoma and colorectal cancer. Ruixin leverages its expertise in medicinal chemistry to build a robust pipeline of targeted therapies aimed at addressing significant unmet medical needs. The company operates out of the Guangzhou International Bio Island and has received backing from prominent venture capital firms like 6 Dimensions Capital.